Goldman Sachs
LBRX

Goldman Sachs’s LB Pharmaceuticals LBRX Stock Holding History

Goldman Sachs’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
576,456
+212,657
+58% +$6.25M ﹤0.01% 2694
2026
Q1 		$8.97M Buy
363,799
+60,684
+20% +$1.4M ﹤0.01% 3161
2025
Q4 		$6.75M Sell
303,115
-40,408
-12% -$706K ﹤0.01% 3468
2025
Q3 		$5.42M Buy
+343,523
New +$5.45M ﹤0.01% 3560

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Goldman Sachs's LBRX Position: Q2 2026 in Review

Goldman Sachs increased its LB Pharmaceuticals (LBRX) stake by 58% in Q2 2026, buying an estimated $6.25M and bringing the position to 576,456 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Goldman Sachs first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Goldman Sachs held 576,456 shares of LB Pharmaceuticals worth $18.7M as of Q2 2026.
  • Goldman Sachs bought 212,657 LB Pharmaceuticals shares in Q2 2026, an estimated $6.25M.
  • LB Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2694 holding.
  • Goldman Sachs first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.